What is Chronic Lymphocytic Leukemia? This cancer affected Hulk Hogan before his death. Wrestling legend Hulk Hogan died from a heart attack on July 24 at age 71. Official records also revealed he had ...

In " Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels continue ...

In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard therapy for patients with chronic lymphocytic leukemia (CLL) who have ...

Medical experts provide an overview of chronic lymphocytic leukemia (CLL), including its typical symptoms and diagnostic process. They also will inquire about key prognostic factors and their impact ...

One expert explains why most of the time clinical trial enrollment is ‘the correct answer’ for patients. By participating in clinical trials, patients with cancer have the opportunity to find ...

Time-limited acalabrutinib plus venetoclax improves outcomes vs chemoimmunotherapy, offering the first FDA-approved all-oral fixed-duration CLL option, explains Adam Kittai, MD.

IGHV mutational status has long been used by clinicians to predict how CLL will behave and when treatment may be needed. 2 ...

Explore 2026 CLL frontline choices, from all-oral acalabrutinib–venetoclax to MRD-guided care, plus pipeline advances and ...

MILAN — Is chronic lymphocytic leukemia (CLL) progression primarily driven by genetic mutations or by external cues from the tumor microenvironment? Despite major strides in targeted therapies, CLL ...

About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...

5-year follow-up from SEQUOIA study demonstrated treatment with BRUKINSA reduced the risk of progression or death by 71% compared to bendamustine-rituximab in patients with treatment-naïve CLL, ...

BRUKINSA plus venetoclax demonstrated high response rates and a favorable safety profile across CLL patient types in SEQUOIA Arm D, including those with high-risk del(17p) mutational status At 5-year ...